On the basis of the high specificity of the BRAF mutation for PTC, several studies have proven the usefulness of the BRAF mutation for identifying PTC from indeterminate cytological results.28,37–43 However, in the general population, testing for the BRAF mutation alone might not be sufficient for evaluating thyroid nodules because of its relatively low sensitivity, approximately 44%, for the diagnosis of PTC.35 This evidence concerns the gene BRAF and thyroiditis.